New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Aligos Therapeutics, Inc. (ALGS) vs Dare Bioscience, Inc. (DARE)

Aligos Therapeutics, Inc. and Dare Bioscience, Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and Dare Bioscience, Inc. are of similar size ($8.9M and $8.8M). Dare Bioscience, Inc. grew revenue faster over the last twelve months: 2,571.6% against 1,171.6%. Aligos Therapeutics, Inc. has the higher net margin (−197.0% vs −749.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Aligos Therapeutics, Inc. leads on 10 and Dare Bioscience, Inc. on 5.

Valuation

Metric ALGS DARE Biotechnology median
P/E n/m n/m 8.49
P/S 0.39 5.06 8.56
P/B 1.15 3.05 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.26 0.52 0.69
EV/Sales (0.56) (3.11) 8.00
Earnings yield (512.10%) (166.32%) (35.81%)
Free cash flow yield (529.27%) (257.09%) (25.41%)

Profitability

Metric ALGS DARE Biotechnology median
Gross margin 100.00% 47.37% 70.18%
Operating margin (215.55%) (746.14%) 0.00%
Net margin (197.01%) (749.83%) 0.00%
Free cash flow margin (204.07%) — 0.00%
Return on equity (159.46%) (407.13%) (51.58%)
Return on assets (84.46%) (40.05%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALGS DARE Biotechnology median
Revenue growth (TTM) 1,171.58% 2,571.63% 7.20%
EPS growth (last fiscal year) 88.30% (150.00%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALGS DARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.77 1.23 4.79
Net debt to EBITDA 0.87 2.07 1.01

Dividend

Metric ALGS DARE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALGS DARE Biotechnology median
Market cap 8.81m 8.89m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack